- Home
- SMMT
as 11-15-2024 4:00pm EST
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | MENLO PARK |
| Market Cap: | 14.5B | IPO Year: | N/A |
| Target Price: | $34.75 | AVG Volume (30 days): | 2.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.28 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.88 - $33.89 | Next Earning Date: | 10-30-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Summit Therapeutics Inc. News
SMMT Breaking Stock News: Dive into SMMT Ticker-Specific Updates for Smart Investing
Investor's Business Daily
3 days ago
Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics
TipRanks
7 days ago
TipRanks’ ‘Perfect 10’ Picks: 2 Top-Scoring Stocks for the Rest of 2024
Motley Fool
9 days ago
2 Hot Biopharma Stocks to Buy and Hold for 5 Years
Motley Fool
13 days ago
Why Summit Therapeutics Stock Was a Winner Today
Benzinga
13 days ago
Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo
GuruFocus.com
13 days ago
Summit Therapeutics Leads the Parade of Big Gainers
Motley Fool
14 days ago
3 Magnificent Stocks Under $100 to Buy in November
Zacks
17 days ago
Summit Therapeutics Posts Wider-Than-Expected Loss in Q3, Nil Sales
Compare SMMT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SMMT Summit Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.